Enhertu Wins US Breakthrough Status in High‑Risk Early HER2‑Positive Breast Cancer
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca and Daiichi Sankyo’s HER2-directed antibody drug conjugate Enhertu has received US FDA Breakthrough Therapy Designation as a post‑neoadjuvant treatment for adults with HER2‑positive early breast cancer who have residual invasive disease and a high risk of recurrence after initial therapy. The designation, based on positive Phase III DESTINY‑Breast05 data showing superior outcomes versus current standard T‑DM1, marks the drug’s tenth such status and underscores its potential to reshape care in early‑stage, high‑risk HER2‑positive disease, complementing an expanding label that already spans multiple metastatic breast, lung, gastric and solid tumour indications and reinforcing AstraZeneca’s and Daiichi Sankyo’s competitive leadership in the fast‑growing ADC oncology market.
The most recent analyst rating on (GB:AZN) stock is a Sell with a £105.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
AstraZeneca’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic expansions and product approvals further enhance its outlook. However, the high valuation and moderate technical indicators slightly temper the overall score.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company with a strong oncology franchise, while Daiichi Sankyo is a Japanese pharmaceutical group; together they focus on developing and commercialising next‑generation antibody drug conjugates (ADCs) such as Enhertu for HER2-targeted cancers across breast, lung, gastric and other solid tumours, where they have built a broad, late‑stage clinical programme and multiple worldwide approvals.
Average Trading Volume: 2,249,463
Technical Sentiment Signal: Strong Buy
Current Market Cap: £212B
See more insights into AZN stock on TipRanks’ Stock Analysis page.
